GXDX Genoptix, Inc. (MM)

Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Genoptix, Inc. (“Genoptix” or the “Company”) (NASDAQ:GXDX) related to the Company’s agreement to be acquired by Novartis AG (“Novartis”). The proposed transaction is valued at approximately $470 million.

Under the terms of the definitive merger agreement entered into by the parties, Novartis will commence an all-cash tender offer to acquire all outstanding shares of Genoptix common stock for $25.00 per share. The proposed transaction was unanimously approved by the Company’s board of directors. The transaction is expected to be completed within the first half of 2011. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the proposed transaction by Genoptix’s board of directors.

If you are a shareholder of Genoptix, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Genoptix, Inc. (MM) (NASDAQ:GXDX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024

Genoptix, Inc. (MM) (NASDAQ:GXDX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024